<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521479</url>
  </required_header>
  <id_info>
    <org_study_id>P2c</org_study_id>
    <nct_id>NCT03521479</nct_id>
  </id_info>
  <brief_title>A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis</brief_title>
  <official_title>A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Squarex, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Squarex, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective: To assess local and generalized adverse events with repeat topical&#xD;
      application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent&#xD;
      herpes labialis (4 or more episodes in the previous 12 months).&#xD;
&#xD;
      Secondary Objective: To assess efficacy of repeat topical application of 2% and 0.5% SADBE in&#xD;
      the prevention of herpes labialis episodes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary oral infection with the herpes simplex virus (HSV) typically occurs at a young age,&#xD;
      is asymptomatic, and is not associated with significant morbidity. After primary oral&#xD;
      infection, HSV may persist in a latent state in the trigeminal ganglion and later reactivate&#xD;
      as the more common herpes labialis, or &quot;cold sores.&quot; Common triggers for reactivation are&#xD;
      well known and include ultraviolet light, trauma, fatigue, stress, fever, inflammation, and&#xD;
      menstruation. These lesions affect up to 45 percent of the U.S. population. They classically&#xD;
      manifest as a well-localized cluster of small vesicles along the vermilion border of the lip&#xD;
      or adjacent skin. The vesicles subsequently rupture, ulcerate, and crust within 24 to 48&#xD;
      hours. Spontaneous healing occurs over seven to 10 days.&#xD;
&#xD;
      In immunocompetent patients, herpes labialis usually is mild and self-limited. However, pain,&#xD;
      swelling, and cosmetic concerns may prompt physician consultation. Orally administered&#xD;
      antiviral agents, such as acyclovir (Zovirax) or valacyclovir (Valtrex), have a modest&#xD;
      clinical benefit if initiated during the prodrome. Topical treatment with 1% penciclovir&#xD;
      cream (Denavir) may reduce healing time and pain slightly, even if initiated after the&#xD;
      prodrome. However, reduction in healing time with systemic or topical agents is modest.&#xD;
&#xD;
      Squaric acid dibutyl ester (SADBE) is a topical immunotherapeutic agent used in the treatment&#xD;
      of verruca vulgaris and alopecia areata. During a recent FDA Compounding Advisory Committee&#xD;
      Meeting, it was recommended that squaric acid dibutylester be included on the list of bulk&#xD;
      drug substances allowed for use in compounding under section 503A of the Federal Food, Drug,&#xD;
      and Cosmetic Act. And SADBE has now been so listed under section 503A.&#xD;
&#xD;
      A study completed by Lee et al of 29 patients with recalcitrant warts demonstrated complete&#xD;
      clearance in 69% of patients with application every 2-4 weeks. Silverberg et al showed a&#xD;
      complete clearance in 58% of patients (n=61) when SADBE was applied 3 times weekly. A&#xD;
      placebo-controlled clinical study completed at Massachusetts General Hospital showed that&#xD;
      squaric acid prevented recurrence of herpetic lesions. The effect of SADBE of delaying new&#xD;
      herpes labialis outbreaks was highly significant (p&lt;0.01) as compared to placebo.&#xD;
&#xD;
      Primary Objective: To assess local and generalized adverse events with repeat topical&#xD;
      application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent&#xD;
      herpes labialis (4 or more episodes in the previous 12 months).&#xD;
&#xD;
      Secondary Objective: To assess efficacy of repeat topical application of 2% and 0.5% SADBE in&#xD;
      the prevention of herpes labialis episodes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study drug out of specification&#xD;
  </why_stopped>
  <start_date type="Actual">March 12, 2018</start_date>
  <completion_date type="Actual">October 5, 2019</completion_date>
  <primary_completion_date type="Actual">October 5, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will receive on a double blind basis one of two treatment regimens:&#xD;
Group A: 15 subjects, treated with 2% SADBE on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8.&#xD;
Group B: 15 subjects, treated with 2% SADBE on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8.&#xD;
And subjects will be recruited on an open label basis to two other treatment regimens:&#xD;
Group C: 15 subjects, treated with 2% SADBE on day 0, month 3, and month 6.&#xD;
Group D: 15 subjects, treated with 2% SADBE on day 0 and month 6.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The double-blinding only applies between groups A and B. Subjects for groups C and D will be recruited on an open label basis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Local and Generalized Adverse Events</measure>
    <time_frame>9 months</time_frame>
    <description>Local and generalized adverse events with repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Herpes Labialis</condition>
  <condition>HSV</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0, month 3, and month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Squaric Acid Dibutyl Ester</intervention_name>
    <description>Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <other_name>Repeat Dosing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 and ≤ 65&#xD;
&#xD;
          2. Clinical diagnosis of herpes labialis, which may be made at the screening visit based&#xD;
             on the patient's self-reported history of symptoms. An active herpes labialis outbreak&#xD;
             at the time of entry into the clinical trial will neither be required nor will be an&#xD;
             exclusion criterion.&#xD;
&#xD;
          3. Self report having four (4) or more episodes of herpes labialis in the past 12 months.&#xD;
&#xD;
             Subjects will NOT be told that four-or-more episodes in the previous 12 months is the&#xD;
             entry criterion. Subjects will be asked &quot;How many separate episodes of cold sores have&#xD;
             you had in the previous 12 months?&quot; They will be included if they give an answer of&#xD;
             four or more and excluded if they give an answer of three or fewer.&#xD;
&#xD;
          4. At least half of the subject's episodes of the previous 12 months should be vesicular&#xD;
             in nature and at least half preceded by prodromal symptoms. Prodromal symptoms may&#xD;
             include tingling, itching, burning or pain before the development of a herpetic&#xD;
             lesion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating females.&#xD;
&#xD;
          2. Current or recurrent non-herpetic infection or any underlying condition that may&#xD;
             predispose to infection or anyone who has been admitted to the hospital due to&#xD;
             bacteremia, pneumonia or any other serious infection in the last 12 months.&#xD;
&#xD;
          3. Therapy with glucocorticoid or immunosuppressants at time of recruitment or within&#xD;
             past 4 weeks prior to the screening visit, or at any time during the study (including&#xD;
             inhaled corticosteroids for asthma), except for topical steroids in sites other than&#xD;
             face.&#xD;
&#xD;
          4. History of malignancy (except patients with surgically cured basal cell or squamous&#xD;
             cell skin cancers).&#xD;
&#xD;
          5. History of organ transplantation.&#xD;
&#xD;
          6. HIV-positive status determined by history at screening or known history of any other&#xD;
             immunosuppressive disease.&#xD;
&#xD;
          7. Severe co-morbidities (CHF [NYHA class II or worse], MI, CVA or TIA) within 3 months&#xD;
             of screening visit, current unstable angina pectoris or oxygen-dependent severe&#xD;
             pulmonary disease.&#xD;
&#xD;
          8. Known hypersensitivity to Dimethyl sulfoxide (DMSO).&#xD;
&#xD;
          9. Any condition judged by the investigator to cause this clinical trial to be&#xD;
             detrimental to the patient.&#xD;
&#xD;
         10. Subject is currently enrolled in another investigational device or drug trial(s), or&#xD;
             subject has received other investigational agent(s) within 28 days of the screening&#xD;
             visit.&#xD;
&#xD;
         11. Previous exposure to SADBE (squaric acid or squaric acid dibutyl ester).&#xD;
&#xD;
         12. Subject has an abnormal skin condition (e.g., acne, eczema, rosacea, psoriasis,&#xD;
             albinism, or chronic vesiculo-bullous disorder) that occurs in the area ordinarily&#xD;
             affected by herpes labialis&#xD;
&#xD;
         13. Subject has an abnormal skin condition (e.g., eczema, rosacea, psoriasis, albinism, or&#xD;
             chronic vesiculo-bullous disorder) that occurs in the inner aspect of either upper arm&#xD;
             (the area where drug will be applied).&#xD;
&#xD;
         14. Subject has had a vaccine for either HSV-1 or HSV-2.&#xD;
&#xD;
         15. Subject has had treatment with anti-viral therapy (including ABREVA) within 2 weeks&#xD;
             before first dose of SADBE or at any time during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>International Research Partners, LLC</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prism Clinical Research, LLC</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 29, 2018</study_first_submitted>
  <study_first_submitted_qc>April 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <results_first_submitted>May 19, 2021</results_first_submitted>
  <results_first_submitted_qc>May 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 15, 2021</results_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Squaric Acid</keyword>
  <keyword>SADBE</keyword>
  <keyword>Squaric acid dibutyl ester</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Labialis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squaric acid dibutyl ester</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT03521479/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
        </group>
        <group group_id="P3">
          <title>Group C</title>
          <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0, month 3, and month 6.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
        </group>
        <group group_id="P4">
          <title>Group D</title>
          <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and month 6.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0, month 3, and month 6.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
        </group>
        <group group_id="B4">
          <title>Group D</title>
          <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and month 6.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="11.3"/>
                    <measurement group_id="B2" value="39.2" spread="10.1"/>
                    <measurement group_id="B3" value="47.1" spread="12.4"/>
                    <measurement group_id="B4" value="47.2" spread="13.1"/>
                    <measurement group_id="B5" value="43.94" spread="11.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American or Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Local and Generalized Adverse Events</title>
        <description>Local and generalized adverse events with repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0, month 3, and month 6.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
          </group>
          <group group_id="O4">
            <title>Group D</title>
            <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and month 6.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Local and Generalized Adverse Events</title>
          <description>Local and generalized adverse events with repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Localized reaction (rash, erythema, itching/pruritus, warmth/burning) at application site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized adverse events (related, possible or greater)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized adverse event (unrelated)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>172 days</time_frame>
      <desc>At risk participants listed below as 30 because the 10 participants in each group was counted on 3 separate occasions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
        </group>
        <group group_id="E3">
          <title>Group C</title>
          <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0, month 3, and month 6.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
        </group>
        <group group_id="E4">
          <title>Group D</title>
          <description>Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and month 6.&#xD;
Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Day 0-20</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Day 21-41</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Day 42+</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hugh McTavish</name_or_title>
      <organization>Squarex LLC</organization>
      <phone>6512078270</phone>
      <email>hmctavish@squarex-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

